valuation thoughts, page-300

Don't want to burst the bubble or the dreaming because I would love this too, but I don't think we'll get close to this level realistically and especially in this market we are lucky to have a 1-2B market cap in the next 5 years. We're trying to hit solid tumors with CAR-T which has been very difficult so we might suffer more downturn for any result that doesn't show complete responses or any average results. With that said, if we do show complete responses or significant increases in overall survival compared to SOC in solid tumors, we may rocket because this is very rare.

If they targeted blood tumors first with CAR-T or their CAR-NK, we might have more success and the share price momentum first as those therapies are just more potent in that disease area. However, the strategy seems to be to target the most difficult barrier (CLTX CAR-T in GBM and CDH17 CAR-T in NET). The initial results from the CORE CAR-NK platform from Case Western is a good foreshadowing of how cell therapies work in blood tumors and solid tumors:

If you look at biotech companies having multiple programs and targetting both solid and blood tumors, you will see some big rises in share prices followed by big downturns or vice versa. That is just the very nature of a multi-program biotech company.